Company - Capstan Therapeutics We are a diverse team of experts integrating advancements in CAR-T therapy, mRNA, and LNPs, with rigorous focus to engineer transformative medicines
Capstan Therapeutics to Present Preclinical Data on Lead In Vivo . . . SAN DIEGO, September 26, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform,
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T . . . SAN DIEGO, November 18, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced preclinical data
Capstan Therapeutics Launches with $165 Million to Deliver on the . . . – Capstan’s foundation is built on research developed by world-renowned mRNA and cell therapy scientists and clinicians at the University of Pennsylvania – Therapy development focused on cell type-specific engineering
Capstan Therapeutics to Participate in Jefferies Global Healthcare . . . SAN DIEGO, May 28, 2025 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan